RA Management: What’s the First-Line Treatment Option in Patients with Low Disease Activity?

The ACR released a new guideline for the management of rheumatoid arthritis in June. The guideline addresses treatment with disease-modifying anti-rheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs and targeted synthetic DMARDs, the use of glucocorticoids and the use of DMARDs in certain high-risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections and nontuberculous mycobacterial lung disease). Read the full article from The Rheumatologist, June 2021: "The ACR Releases an Updated Treatment Guideline for Rheumatoid Arthritis."